UCB UCB SA

EBR · BE · Healthcare · Biotechnology · ucb.com
307.34USD279.60 EUR · EBR-1.27%Mkt Cap: 58.60B USDP/E: 24.70

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn'…

Institutional holders12 on file

Key Statistics

Company
Market Cap58.60B USD
Enterprise Value62.45B USD
Revenue (TTM)9.37B USD
Gross Profit6.32B USD
Net Income (TTM)1.71B USD
Revenue/Share49.21 USD
Last Price307.34 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9.0K
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINBE0003739530
Valuation
P/E (Trailing)24.70
P/E (Forward)18.69
PEG1.39
EV/EBITDA18.11
EV/Revenue6.67
P/S6.25
P/B4.57
EPS (TTM)12.44 USD
EPS (Forward)16.44 USD
52W Range
217.0479% of range331.08
52W High331.08 USD
52W Low217.04 USD
Profitability
Gross Margin74.29%
Oper. Margin29.47%
EBITDA Margin36.81%
Profit Margin20.13%
ROE14.34%
ROA8.58%
ROIC16.07%
ROCE14.57%
Growth
Revenue Growth22.50%
Earnings Growth134.80%
Cash Flow & Leverage
Operating CF2.52B USD
CapEx (TTM)493.54M USD
FCF Margin11.39%
FCF Yield1.82%
Net Debt3.10B USD
Net Debt/EBITDA0.90
Net Debt/FCF2.91
Balance Sheet
Debt/Equity0.21
Current Ratio1.20
Quick Ratio0.72
Book Value/Sh67.19 USD
Cash/Share4.42 USD
Dividends
Fwd Div Rate1.59 USD
Trail. Div Rate1.59 USD
Div. Yield0.51%
5Y Avg Yield0.95%
Payout Ratio12.81%
Ex-Div DateMay 4, 2026
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)328.26 USD
Upside (mean)+6.8%
Target Range228.63 USD – 379.22 USD
228.63+6.8% to mean379.22
# Analysts19
Ownership
Shares Out.190.66M
Float120.10M
Insiders36.28%
Institutions39.72%
Technical
SMA 50261.00 (+17.8%)
SMA 200268.15 (+14.6%)
Beta0.11
S&P 52W Chg12.00%
Avg Vol (30d)300.67K
Avg Vol (10d)239.99K
Technical Indicators
RSI (14)57.9
MACD13.3369
MACD Signal16.8555
MACD Hist.-3.5186
BB Upper333.25 USD
BB Middle313.01 USD
BB Lower292.77 USD
BB Width12.93%
ATR (14)8.525 USD
Vol Ratio (20d)0.92x

About UCB (EBR: UCB)

›

UCB (EBR: UCB) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 9,000 employees.

The shares were at 279.60 EUR on 20 November 2026, up 22.5% over 52 weeks. Its 52-week range is 197.45 EUR to 301.20 EUR: the price is 7.2% below the high and 41.6% above the low.

At a market capitalisation of 53.31B EUR, it trades at 24.7 times trailing earnings and 18.7 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 34.3, a discount of 28% for UCB. It pays a dividend yielding 0.51% (it pays out 13% of its earnings), against a median of 1.39% among the dividend payers in that peer group.

UCB reports return on equity of 14.3%, an operating margin of 29.5% and revenue up 22.5% year over year.

Its debt exceeds its cash by 2.82B EUR, a debt-to-equity ratio of 0.21. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 19 analysts cover the stock, with an average rating of Buy; their mean price target of 298.63 EUR is 6.8% above the current price. The next earnings report is expected on 24 February 2027.